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constructed, was always rooted in 'biological' features;
that is, the characteristics used to classify individuals into
races were always assumed to have a basis nontrivially
rooted in human biology (5). 
Many scientists have been satisfied to use false
statistics, poor methodology, and illogical conclusions
to "prove" the theory that biology is a predictor of
culture, without regard for real evidence stating the
opposite (6). 
Without any concrete evidence, why would scientists
want to go to all the trouble to create distinct biological
races? According to Maria Castagna and George J. Sefa
Dei, "whites created different 'sciences' and 'scientific'
theories to justify, legitimize and maintain the existing
social order" (6). Therefore, rather than being based
solely in objective observation, scientific racism is a
scientific tradition in which biology is used not only to
prove the existence of race, but also, to maintain
existing social hierarchies. 
The recent Food and Drug Administration (FDA)
approval of BiDil®, a congestive heart failure drug
created by NitroMed®, looks to continue and reinforce
this tradition of scientific racism. Marketed specifically
to African Americans, it is the first drug to specifically
target a racial group (7). A combination of 20mg of
isosorbide dinitrate and 37.5mg of hydralazine
hydrochloride (8), the two components have "been used
for years to treat high blood pressure and agina (chest
pain)" (9). While isosorbide dinitrate "helps the body
make a tiny molecule called nitric oxide [. . .]
hydralazine helps prevent its rapid destruction" (9).
This creation of nitric oxide allows the arteries to widen
and lets blood travel through them more easily,
"decreasing the heart's workload" (9). While
researchers believe that BiDil® works best in
QUESTION: What is the difference between black
natives slicing up a white missionary, and a white mob
lynching a helpless Negro? Answer: very little - and,
for the victims, none at all. Whatever the reasons,
whatever the excuses, whatever the motives, the basic
behaviour mechanism is the same. They are both cases
of members of the in-group attacking members of the
out-group. - Desmond Morris (1)
In Racialized Boundaries: Race, Nation, Gender,
Colour and Class and the Anti-Racist Struggle, Floya
Anthias and Nira Yuval-Davis state: 
Race is one way by which the boundary is to be
constructed between those who can and those who cannot
belong to a particular construction of a collectivity or
population. In the case of race this is on the basis of an
immutable biological or physiognomic difference which
may or may not be seen to be expressed mainly in culture
or life-style but is always grounded on the separation of
human populations by some notion of stock or collective
heredity of traits (2)
While Anthias and Yuval-Davis' statement reflects
the most common association between race and
genetically inheritable traits, the science involving this
subject is often imprecise, and more often, simply false
(3). The phrase, "some notion of stock or collective
heredity of traits" (2), implies an uncertainty towards
what has consistently throughout history been
understood as a proven biological truth, regardless of
evidence stating the opposite (4). In fact, 
[t]he Western concept of race, although socially
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individuals that produce low levels of nitric oxide, "a
few small studies suggest that blacks have more
difficulty making or using nitric oxide than whites. Not
all blacks have this trouble of course, nor does everyone
else have plenty of nitric oxide" (9).
BiDil®'s approval raises important questions about
the future of genetic-based medicine, as "some experts
worry about the precedent of accepting race as a crude
marker for underlying biological differences - which
could still leave many individuals being treated with
drugs that don't work well for them" (7). By using race
to distinguish who is more suited to use a drug,
pharmaceutical companies are practicing a modern
form of scientific racism, and ignoring the social
reasons as to why African Americans are twice as likely
to develop congestive heart failure (10). 
To understand modern scientific racism, however, it
is important to understand what scientific racism is, and
how it has been used in the past. While science has the
reputation of objectively testing theories using the
scientific method, scientific racism is the exact
opposite. It seeks to create definitions of race and
culture based on opinion and extremely questionable
evidence: "Supposed scientific evidence was
marshalled, to establish both the existence of different
racial types, and their depiction within a hierarchy of
superior and inferior, where the Black was regarded as
inferior" (2). The important distinction between science
and scientific racism is that the creation of separate
racial categories was not solely for the sake of a
biological system of classification, but rather for
political means: 
Preconceived notions of European superiority led to a
nonscientific justification for European social dominance
[. . .] Such justification could then have been transformed
into a biological theory based on biased science intended
to validate European preconceptions (5). 
These preconceptions were based on the idea that
nature, and not social forces, created divisions in
society, and consequently "the physiological, cultural,
and economic woes of the poor and the nonaffluent
'middling classes' were scientifically ordained by
Nature, and therefore neither preventable nor
reversible" (3). This concept of hereditary social traits is
extremely important to scientific racism as it explains
social inequalities not in terms of the society failing to
provide for its citizens, but rather a group’s failure to
have superior breeding.
One of the first racial theories to be developed was
that of polygenism, "which held that the human races
had been created separately" (5), authored by Swiss
physician Paracelsus in 1520. This theory held that God
had created the white race as superior, and therefore
separate to other races, creating a hierarchy of races as
measured by God (5). While polygenism was not
"science", the attitude it created towards other ethnic
groups allowed scientific racism to flourish in light of
the slave trade, which was seen to reinforce polygenistic
beliefs:
The slave trade not only brought together populations that
previously had been geographically separated but also
brought them together under conditions of manifest social
inequality. That is, phenotypic characteristics were used to
symbolize social status (5). 
European success in dominating other civilizations was
seen as evidence from God of their superior genetic
heritage.
The modern biological system of classification,
however, "began with Carolus Linnaeus (1707-1778),
who developed the binomial nomenclature system to
classify and organize plants and animals" (5). Linnaeus'
classification system was extremely important in
determining a system of classification based on specific
- normally phenotypic - traits. His description of Homo
Sapiens includes four distinct varieties: " H. sapiens
europaeus, H. sapiens afer, H. sapiens asiaticus, and H.
sapiens americanus" (5), ranging from H. sapiens
europaeus on the one end, to  H. sapiens afer at the
other, keeping "consistent with the general views and
approach of other eighteenth-century naturalists
examining race" (5). While Linnaeus' classification
system and taxonomy in general "is directly related to
one's central theory of how and why to classify
organisms into groups" (5), it is important to recognize
the social placement of those doing the classifications.
While most naturalists argued as to the relative
placement of other races, "they concurred that
Europeans occupied the highest position on the scale of
nature" (5). 
Although Thomas Jefferson spoke of all men as being
"created equal", observations of his own slaves led him
to believe that "Negro inferiority was obvious, [and] the
criteria by which it might be established would have to
be determined by science" (5). One of the most
influential pre-Darwinian racial theorists, Jefferson's
call for science to determine the obvious "inferiority" of
African Americans is an extremely important stage in
the evolution of scientific racism. While earlier
naturalists concluded that there was a "hierarchy of
human races, they saw all races as members of the
human species" (5). 
The beginning of the nineteenth century, however,
saw a revival of polygenist thinking and a shift in the
racial paradigm. While there was no question regarding
the inferiority of the "Negro race", there was "debate
concerning whether Negroes represented a distinct
species from the other human races" (5). Polygenists
such as Louis Agassiz, Samuel Morton, Josiah Nott and
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George Robin Gliddon used various methods, including
the measurement of cranial volume, to determine
genetic inferiority of the African race (5). Their
evidence failed to suggest any form of genetic
difference based on race, yet they continued to
proliferate scientific racism throughout their lives (5).
While these earlier theories failed to provide any
form of concrete proof surrounding many biological
issues, Charles Darwin's theory of evolution and natural
selection provided logical evidence that addressed "the
origin and maintenance of biological diversity" (5).
Darwin's theory succeeded where others did not due to
"directly observable biological phenomena, such as the
resistance to pesticides and antibiotics, our ability to
produce new food crops, and the postponement of the
aging of laboratory animals" (5). His theory has had
such an impact on genetics and race that "[a]fter
Darwin, any ranking of human beings by specific
criteria would need scientific (that is, testable)
justification" (5).
Furthering Darwin's concept of natural selection,
sociologist Herbert Spencer "coined the term 'survival
of the fittest'" (5) in response to growing social
inequality in both England and the United States.
Adapting Darwin's evolutionary theories to the social
landscape, Spencer would conclude that millionaires
"were the product of natural selection, the bloom of the
competitive society" (5). Essentially, Spencer's social
darwinism mirrored polygenism without the religious
connotations; successful groups of people, whether
based on race or other factors were a product of
biologically superior genetic inheritance. This thinking
would lead others such as Sir Francis Galton to develop
the areas of eugenics, pseudoscience, and
psychometry1. These new "sciences" would retain the
same irresponsible practices and methodologies as their
former iterations. 
Yet, while scientific racism appears to be a result of
past irresponsible scientific practice, it has hardly fallen
out of popular favour. In his 1997 book, ‘Why Race
Matters’, Michael Levin is quoted as saying: "If breeds
of dog may differ in intelligence and temperament,
there seems to be no reason evolution could not have
differentiated human groups along similar lines" (11).
Responding to current sociological claims that race is
socially constructed (5), Levin states: "As the
accumulating evidence has made group differences
harder to deny, one is apt to be told they do not matter"
(11). Continuing the tradition of scientific racism, Levin
does not provide any substantial evidence to support his
claims, instead choosing to discuss the genetic
inheritance of particular species of animals, heritability
of personality, and IQ testing between both blacks and
whites (11). Vincent Sarich and Frank Miele similarly
discuss race in their 2004 book, ‘Race: The reality of
human differences’, discussing social and scientific
factors that "prove" the existence of different races.
Like Levin, Miele and Sarich provide faulty and
illogical evidence to support their claims: 
One must look to the breeds of dogs to find a comparable
degree of within-species differences in morphology. We
also point out other aspects in which human diversity in
morphology, pharmacogenetics (body chemistry), and
behaviour more closely parallels our best friends (the
dogs) than our nearest relative (the apes), and what that
reveals about the origin of our species (12)
What Levin, Sarich and Miele fail to recognize is that
"individual genetic traits are inherited independently"
(5), not as a group. Therefore culture, intelligence,
athletic ability, et cetera cannot be racially linked due to
the independent nature of these genetic traits. 
A further illustration of this would be the commonly
misused example of sickle disease and malaria "to
support the biological foundation of race" (13). While
sickle disease is "caused by a specific mutation in the
haemoglobin gene [. . .] [it] appeared in, at least, four
independent regions of the world, including Central and
North Africa, Spain, Arabia, and India" (13). Bernard
Swynghedauw states:
In homozygous persons, the mutation is fatal and patients
died from severe anaemia and its consequences. In
contrast, in heterozygous persons, the mutation provides a
selective advantage because patients are resistant to
malaria [. . .], and the contemporary map of sickle disease
can be superimposed on that of malaria. In fact, such an
evolutionary advantage was crucial for the geographic
distribution of the disease in three continents [. . .] between
black and white Africans, Spanish, Arabs and Indians (13).
Swynghedauw continues to make clear the issue that
"race has nothing to do with such a distribution, and, in
no sense, can sickle disease support the assumption that
race or even ethnicity has a biological basis" (13).
While interbreeding populations will most likely share
genetic traits - such as resistance to or susceptibility to
particular diseases - these traits cannot be assumed by
phenotypic differences or racial classifications as is
done in the work of Levin, Sarich and Miele suggests.
Similarly, difficulties arise in not only finding
societies composed solely of phenotypically
homogeneous individuals, but also in finding
individuals that identify themselves as made up of
distinct races. Swynghedauw describes the "human
race" as "an extremely vague concept, with several, and
contradictory definitions, mixing geographical
(Asians), religious (Jews), and imaginary (Caucasians)
origins, together with biologic phenotypes (Black)"
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(13). He also raises an interesting point:
Race is a parameter that cannot be measured accurately
and cannot even be defined using objective criteria. Why
skin colour? Why not height, which confers a strong
evolutionary advantage? Or baldness - which is neutral?
How do we classify mulattos? If one drop of black blood
is enough to become black, why not the reverse? (13).
Barring the difficulties in trying to measure and
classify race, "data from the last US census showed that
even self-identification of race was problematic, since 7
million people identified themselves as members of
more than one race, and about 800,000 respondents said
they were both black and white" (13). In our
cosmopolitan world it is becoming more and more
difficult to identify the "racial" identity of an individual
and according to John E. Clark, president of the
Association of Black Health-System Pharmacists
(ABHP), racial identification in terms of skin colour is
not enough: "For me to call someone 'black' because
they [have] black skin may be inappropriate because
they may not see themselves as that" (8). If there was
ever such a thing as genetically-distinct "races", they
have long-since disappeared due to a world that has
become a global village, blending different ethnicities
and ambiguous racial definitions with multiple
socioeconomic and geographic factors which have the
ability to affect the genetic inheritance of every group
and individual (13).
Going beyond simple phenotypic differences,
however, the results of the Human Genome Project
provide further evidence against the racial concept:
"The genotypes of 'White', 'Black', 'Asians' are
remarkably identical, and there are no more than 0.1%
variations in 35000 genes that have been identified so
far in the human genome" (13). A further study focusing
on the "classical seven 'races'" (13) in different
geographical locations found that "the within-
population diversity is much wider than the between-
population or between-races diversity [. . .] From a
genetic point of view, it is more difficult to distinguish
one person from another, than a black from a
'Caucasian'" (13). As well, Swynghedauw relates the
results of another study in which individuals were
assigned to different "subclusters on the basis of their
genotype, ignoring their actual population or racial
affiliations" (13). This study found similar results, such
that "62% of Ethiopians belong to the same cluster as
Norwegians, together with 21% of the Afro-Caribbeans,
and the ethnic label 'Asian' inaccurately describes
Chinese and Papuans who were placed almost entirely
in separate clusters" (13). The heterogeneous nature of
our society, along with genetic evidence of
commonality between the human "races" distinguishes
modern studies such as these from those by Levin,
Sarich, Miele and others, which demonstrate a
similarity to past scientific racism in their use as an
oppressive tool. While it was historically "believed that
biology held the key to solving social problems" (4), it
has instead often been used as justification for slavery,
oppression, and manifest social inequality.
While scientific racism has predominantly targeted
black populations, Alan Chase argues:
Now, as in 1798, scientific racism remains color-blind and
free of all racial, religious, and cultural biases. It is not
concerned with people but, simply, with what is known as
the maximization of profits and the minimization of taxes
on these profits - particularly when these taxes are
earmarked for promoting the health, education, and
general welfare of the men and women whose labors make
such profits possible in the first place (3).
Chase's statement seems to reflect eerily on the FDA's
recent aproval of BiDil®. While the intentions of
NitroMed® are certainly contentious (16), the use of
science in the marketing of the drug provides African
Americans with rudimentary explanations of why the
drug works better for their particular population:
"Critics point out that while the trials showed that
BiDil® saved lives, they failed to show whether the
drug worked better in blacks than in other groups or that
it worked only in blacks" (14). 
While the past practice of using inadequate science to
demonstrate racial difference is the supreme tenet of
scientific racism, the FDA's approval of BiDil® could
set a dangerous precedent. In a "society obsessed with
the sanctity of 'Science'" (15), scientific evidence is
taken extremely seriously. Yet, this has serious
consequences for the marketing of a race-specific drug,
such as BiDil®. In a letter to the editor of Nature,
Jonathan Kahn points out how "simplifying" research in
various media transforms the meaning to imply fact
(emphasis in bold added):
Los Angeles Times
"[A] report in the journal Nature Genetics last month [that]
listed 29 drugs that are known to have different efficacies
in the two races." 
New York Times
"By one count, some 29 medicines  show evidence of
being safer or more effective in one racial group or
another, suggesting that more targeted medicines may be
coming."
John Entine 
"Only last month, the prestigious journal Nature Genetics
reported that at least 29 medicines have so far been
identified that are either safer or more effective in certain
populations because of genetic differences between those
population groups" (16)
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The basis for the rhetoric used to market BiDil®
specifically to African Americans is somewhat unclear
as the drug has not been tested on various ethnic groups
(9). While African Americans may happen to "respond
better on average to BiDil than whites, [. . .] the drug
will still be ineffective for those who don't possess a
particular cardiac physiology or combination of genes"
(7). The use of scientific evidence to market BiDil®,
regardless of whether the evidence is an accurate
descriptor of whom the drug is targeted to, remains
fixed in the tradition of scientific racism. In one
Newsweek column about the drug, there is a caption
that reads: "Positive discrimination: BiDil, a drug to
prevent heart failure, will be targeted at black patients"
(10). The caption is placed conveniently underneath a
picture of a black patient being tended to by a black
doctor.
NitroMed®'s marketing scheme remains questionable
with further analysis of the media rhetoric. The
corporate sponsor of the A-HeFT trials (African
American Heart Failure Trial), NitroMed® has
consistently linked BiDil® to the "29 medicines"
included in the trial, "paired to give the impression that
there is some 'real' difference underlying racial response
to these drugs" (16). Yet, of all these 29 medicines,
"only 4 [. . .] provide evidence of a genetic cause for the
differential drug response and only an additional 9
provide evidence that 'the association has a reasonable
underlying physiological basis'" (16). Similarly, for the
other sixteen medicines there has been, 
no demonstration of a physiological basis to any observed
difference [. . .] moreover, of the 13 medicines with some
supporting evidence of racial difference, three were ACE
inhibitors, whose claims of racial difference have been
hotly contested in the professional literature, and one was
BiDil (16).
Understanding these issues surrounding BiDil®'s
approval are extremely important for responding to it in
a critical manner. It is significant to note that the FDA
"had rejected the same two-drug pill in 1997, after a
multiracial trial found it less effective than a common
class of drugs [. . .] But in parsing the trial data,
researchers noticed results were strong among African
Americans" (10). The strength of the results in African
American patients led to a new trial in "1050 black
patients. BiDil reduced deaths by 43%, proving so
successful that the trial was stopped early" (7). While
the marketing of BiDil® seeks to emphasize the
positive nature of stopping congestive heart failure in
African American populations, it also seeks to de-
emphasize the evidence that suggests genetic
differences do not discriminate between particular
ethnic groups.
Yet, while BiDil® continues to be marketed as a
positive race-specific drug, Troy Duster, president of
the American Sociological Association describes the
process as "inadequate science [. . .] It's a dangerous
shortcut" (10). Similarly, Gary Puckrein, executive
director of the National Minority Health Month
Foundation states: "This really isn't a race drug, but a
drug that works in specific populations for reasons we
don't yet understand" (14). Regardless of evidence and
claims that suggest otherwise, NitroMed®'s goal of
marketing BiDil® to African Americans assumes a
biological difference - even if they don't believe it. Their
own Dr. Jay Cohn, the University of Minnesota
researcher who developed BiDil® "concedes race is a
crude standard for treatment decisions. 'Unfortunately'
he says, 'we don't have a more precise guide at the
moment'" (10). While the admission of race as a "crude
standard for treatment" (10), suggests a difference
between past scientific racism and BiDil®, the
marketing of the drug is consistent with past scientific
tradition. Similar to Linnaeus' classification system,
NitroMed®'s decision to market BiDil® "exclusively to
members of one race" (10), suggests that biological
differences separate races, indicating who can or cannot
use particular functions of society.
It seems relevant now to refer back to Alan Chase's
comment that scientific racism is based not on people,
but the maximization of profits (3), especially when
investigating NitroMed®'s motives behind getting
approval for a race-specific drug. Kahn suggests that, 
[p]erhaps the answer lies not in medicine, but in
commerce. NitroMed holds a patent for a non-race specific
use of BiDil, which expires in 2007; it also holds a race-
specific patent that lasts until 2020. This extra 13 years of
patent protection may present a compelling commercial
reason for seeking to cast BiDil as a racial drug, even
though to do so is not supported by the medical evidence
(16).
Understanding that BiDil®'s marketing campaign is
not fully supported by medical evidence is important in
demonstrating similarities with past scientific racism.
While pseudoscience, craniology, psychometry, and
polygenism failed to be supported by factual evidence,
their effects and consequences on society remain
extremely large. 
Similarly, "attempts to address genetic difference may
be located at the level of the molecule and targeted by
pharmaceuticals developed and dispensed through the
purportedly impersonal forces of the market" (16). This
in turn creates a dangerous precedent "that the
pharmaceutical industry will move towards single-race
drug studies for its own convenience" (10).
Unfortunately, it seems this practice has already taken
place with NitroMed®'s introduction of BiDi®l, as Dr.
Jay Cohn's admissions that  "we don't have a moreScientific Racism and BiDil 59
precise guide at the moment" (10) indicate that
NitroMed® felt race was the easiest and most
convenient marker of genetic traits at this time. If the
maximization of profits is the sole goal of these
pharmaceuticals there seems to be little "incentive to go
beyond using race or other crude surrogates, when to do
so would entail costly research and might narrow their
target markets" (7). The decision to market BiDil® as a
race-specific drug suggests biological differences
without proper testing of those differences.
More importantly, however, the approval of BiDil®
raises serious questions as to the social consequences of
race-specific drugs. BiDil® appears as a "quick fix" for
what NitroMed®'s marketing suggests is a racial
problem rooted in a myriad of factors, including
biological differences. If past scientific racism used
fixed notions of European dominance to create a
nonscientific rationale for European social authority,
"such justification could then have been transformed
into a biological theory based on biased science
intended to validate European preconceptions" (5).
With this understanding of scientific racism, it seems
clear to link BiDil® to this tradition. Much like
scientific racism's position as a political entity, Kahn
states:
At work here is an appropriation of race as reified in the
BiDil story to serve larger political agendas aimed at
transmuting health disparities, rooted in social and
economic inequality, into mere health differences, rooted
in biology and genetics (16).
In this sense, BiDil®  perfectly reflects the tradition
of scientific racism by using biological differences in
relation to growing social problems. 
One issue that fails to be mentioned in the media
rhetoric and marketing slogans, however, is poverty
among African American populations. As Anthony
Polednak states:
Today, access to and quality of medical care may still
differ for blacks and whites within each level of social
class due to the effects of discrimination and racism [. . .]
populations at highest risk for medical problems  (such as
poor urban black) may have 'limited contact with the
health care system except for emergencies' (17).
If African Americans are twice as common to develop
congestive heart failure and die more often as a result
(10), this may well be directly related to "limited
contact with the health care system except for
emergencies" (17). As well, Polednak's studies indicate
that,
[l]ack of a primary-care physician and health insurance, as
well as a related pattern of receiving care at hospital
emergency rooms rather than physicians' offices, were
associated with noncompliance with treatment and the
occurrence of hypertension emergencies in this case-
control epidemiologic study (17)
Suggesting that African Americans' treatment choice is
a result of "noncompliance of treatment" (17) and not
social inequalities, reinforces scientific and medical
racism. Solely because an African American does not
have health insurance and more often receives care in
emergency situations does not suggest causality
towards noncompliance, but rather a lack of economic
capital to afford those decisions. What is ignored by
NitroMed® and other race-specific drugs is the
common thread between all of Polednak's studies in
which there "appears to be poorer primary care for
blacks" (17), and the lack of questioning as to why this
is taking place.
What NitroMed® also fails to engage is the effect of
discrimination and racism in relation to blood pressure
- a leading cause of congestive heart failure (17).
Although a study in Alameda County, California
involving 51 black and 50 white women 20-80 years old
did not reach statistically significant levels, it is
important to recognize that "racial discrimination was
positively associated with the prevalence of self-
reported high blood pressure among blacks" (17).
Similarly, "the viewing of scenes depicting racist
situations was associated with acute increases in
measured blood pressure or heart rate in samples of
black college students" (17). While these studies may
not have evidence that heart disease is a direct result of
racism and discrimination, their results suggest at least
some connection between the two for African
Americans.
BiDil®'s approval represents both an intentional and
unintentional form of racism inherent through its
creation and its marketing. While NitroMed® is
intentionally distributing the drug to members of one
race, it is also unintentionally reinforcing the unproven
belief that races are separated by distinct biological
differences. The FDA's decision to approve BiDil® "for
sale with a label designating African Americans as the
target population" (7), reinforces scientific racism,
while at the same time, ignoring the social
consequences of a "quick fix" race-specific drug. There
seems to be little difference between NitroMed®'s
decision to create BiDil® and past scientific claims
towards white racial superiority. If the purpose of
scientific racism is to, "blame the hereditary
endowments 'in the blood' of the ill, the uneducated, and
the poor for their chronic (and eminently
environmental) infections and hunger diseases, for their
illiteracy and above all else for their poverty" (3), then
NitroMed® is guilty of symbolically blaming African
Americans for having high levels of congestive heart
failure by failing to recognize and deal with the social
inequalities that lead to such health problems. Similarly,
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the FDA's approval of BiDil® sends a message to other
pharmaceutical companies "that race and genetics
correlate closely enough to provide the basis not only
for general medical practice but also for addressing
specific health disparities" (16). This sets a dangerous
precedent that race can substitute for genetic differences
due to the lack of "a more precise guide" (10).
Pharmaceuticals must "move without delay from blurry
surrogates for drug response to more specific causes"
(7) in order to halt the production of yet another form of
scientific racism and instead, focus on developing the
science that will, once and for all, prove Jefferson's
claim that all men are created equal (5).
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